Metabolic network as a progression biomarker of premanifest Huntington's disease.

ABSTRACT:

Background

The evaluation of effective disease-modifying therapies for neurodegenerative disorders relies on objective and accurate measures of progression in at-risk individuals. Here we used a computational approach to identify a functional brain network associated with the progression of preclinical Huntington's disease (HD).

Methods

Twelve premanifest HD mutation carriers were scanned with [18F]-fluorodeoxyglucose PET to measure cerebral metabolic activity at baseline and again at 1.5, 4, and 7 years. At each time point, the subjects were also scanned with [11C]-raclopride PET and structural MRI to measure concurrent declines in caudate/putamen D2 neuroreceptor binding and tissue volume. The rate of metabolic network progression in this cohort was compared with the corre

SUBMITTER: Tang CC 

PROVIDER: S-EPMC3754266 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature